UBS launched its coverage of Sagimet Biosciences (NASDAQ:SGMT) with a buy recommendation and a $12 price target, calling the company an underappreciated player in the market for liver disorder, ...

Matt Giffen opened up on his experience at Goddard's at Greenwich pie and mash shop, where despite his glowing review, he was clearly unhappy with part of his meal ...

Monsta Mash/ – Following Trump’s win and consequent bull market euphoria, the new crypto assets are receiving a major boost. Pepe coin continues to affirm its place as one of the top-performing tokens ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

The concept of a television sitcom focusing on doctors stationed at the 4077th Mobile Army Surgical Hospital in Uijeonbu, ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

The "Monster Mash" was more than just a graveyard smash — it was also banned in the U.K. for many years! Learn about the ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

This article reveals the top 3 crypto gems with the potential for explosive growth in 2025. For those seeking the next big ...